Sign up for our Oncology Central weekly news round-up

TALAPRO-2 study infographic

Our recent In Focus highlighted the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. Take a look at the infographic summarizing the study below:

FON-2021-0811_INFO

This content is part of our Publication In Focus on TALAPRO-2 – view more content from this feature by clicking here.